Crinetics Pharmaceuticals Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   To elect three nominees (Caren Deardorf, Weston Nichols, Ph.D., and Stephanie S. Okey, M.S.) as Class II directors to serve three-year terms expiring at the 2029 annual meeting.

2. 2

   Ratification of Selection of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   To ratify the audit committee’s selection of PricewaterhouseCoopers LLP (PwC) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

3. 3

   Approval of the Compensation of the Named Executive Officers (Advisory Say-on-Pay

   ManagementBoard: FOR

   A non-binding, advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the proxy statement.

   More detail

   This non-binding say-on-pay proposal asks shareholders to approve the overall compensation program for the Company’s named executive officers as disclosed in the proxy statement. Management seeks this advisory approval to validate its compensation philosophy—which emphasizes pay-for-performance through a mix of base salary, annual cash incentives tied to corporate and individual goals, and multi-year equity awards (stock options and RSUs) that align executives with long-term shareholder value. The compensation committee emphasizes that a significant portion of pay is at risk: corporate achievement accounted for 75–80% of annual incentive calculations and long-term awards vest over multiple years; the committee also capped annual incentive payouts at 150% of target in 2025. Governance measures supporting the program include independent consultant advice (Pearl Meyer), stock ownership guidelines, a clawback policy, and committee oversight by independent directors. The proposal is presented in the context of material company developments in 2025–2026—including FDA approval and initial commercialization of PALSONIFY, advancement of multiple clinical programs, and revenue generation—which management cites as justification for the targeted pay mix and outcomes. While advisory and non-binding, a favorable vote gives the compensation committee important shareholder feedback; the company notes past strong shareholder support (approximately 96.9% in 2025) and commits to consider the vote outcome in future compensation decisions. The Board recommends FOR the proposal arguing the program attracts, retains and motivates leadership necessary to execute strategy, aligns pay with performance and shareholder interests, and incorporates governance safeguards to mitigate excessive risk. The compensation committee’s recommendation is informed by peer benchmarking, internal review of performance goals, and the committee’s judgment about competitive positioning and retention needs.

Upcoming shareholder meetings at Crinetics Pharmaceuticals Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Crinetics Pharmaceuticals Inc 2026 annual meeting?

Crinetics Pharmaceuticals Inc (CRNX) holds its 2026 annual shareholder meeting on Thursday, June 18, 2026.

What is the record date for the Crinetics Pharmaceuticals Inc 2026 meeting?

The record date for the Crinetics Pharmaceuticals Inc 2026 meeting is Monday, April 20, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Crinetics Pharmaceuticals Inc's 2026 meeting?

The board is presenting 2 director nominees at the Crinetics Pharmaceuticals Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Crinetics Pharmaceuticals Inc 2026 meeting?

Shareholders will vote on 3 proposals at the Crinetics Pharmaceuticals Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.